23ME-00610

23ME-00610 is a first-in-class, humanized monoclonal antibody that targets CD200 receptor 1 (CD200R1), an immune checkpoint receptor expressed on T cells and myeloid cells. By binding to CD200R1, 23ME-00610 blocks its interaction with the ligand CD200, which is often overexpressed on certain tumors. This blockade disrupts the immunosuppressive signaling mediated by the CD200–CD200R1 axis, thereby restoring immune cell activity and enhancing antitumor responses. The drug was developed using genetic insights from the large-scale database of 23andMe to identify CD200R1 as a promising immuno-oncology target. It is currently in Phase 2a clinical development for advanced solid malignancies, including neuroendocrine tumors and ovarian cancer[2][4][6]. Early clinical data indicate acceptable safety and preliminary evidence of efficacy in patients whose tumors express high levels of CD200[2][3].

Other names

anti-CD200R1 monoclonal antibodyanti-CD-200R1 monoclonal antibodyanti-CD 200R1 monoclonal antibody